ARTES Biotechnology and Basic Pharma are almost there! The companies are nearing completion of their joint project with the production of recombinant Human Serum Albumin (rHSA) and the first vials are expected to be available this summer.
ARTES, a leading company that specialized in developing and transferring recombinant cell lines and protein production processes from microbial expression systems, and Basic Pharma, a pharmaceutical company focusing on pharmaceutical products, are delighted to announce significant progress in their strategic collaboration to produce recombinant Human Serum Albumin derived from Hansenula yeast.
The teams have been working successfully on the development of rHSA and the project is on track to completion.
The releasing of the first vials containing rHSA are expected this summer as the project approaches the final stages of development. The target audience for the rHSA includes laboratories in academia and industry that require small quantities of high-quality recombinant proteins for their research endeavors.
Melanie Piontek, Business Development Director of ARTES, states: “This collaboration between two successful biotech companies co-marketing products needed in the life sciences has today established a new offering for researchers worldwide. We look forward to seeing this grow in the future.” Michael Piontek, Managing Director of ARTES Biotechnology, added: “The combination of development and manufacturing capabilities at both ARTES and our partner Basic Pharma enables the launch of human albumin today and several new peptides and proteins in the near future.”
Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his satisfaction with the progress; "This collaboration has been instrumental in realizing our vision of offering reagents for research applications. Our joint efforts with ARTES have paved the way for the release of Human Serum Albumin, marking a significant milestone in our strategic collaboration." Bob Kool, Managing Director at Basic Pharma, further emphasized: “The synergy between ARTES and Basic Pharma has been remarkable. We are excited about the potential impact of rHSA and are looking forward in this collaboration towards the development of pharmaceutical grade biologicals.”
ARTES, a leading company that specialized in developing and transferring recombinant cell lines and protein production processes from microbial expression systems, and Basic Pharma, a pharmaceutical company focusing on pharmaceutical products, are delighted to announce significant progress in their strategic collaboration to produce recombinant Human Serum Albumin derived from Hansenula yeast.
The teams have been working successfully on the development of rHSA and the project is on track to completion.
The releasing of the first vials containing rHSA are expected this summer as the project approaches the final stages of development. The target audience for the rHSA includes laboratories in academia and industry that require small quantities of high-quality recombinant proteins for their research endeavors.
Melanie Piontek, Business Development Director of ARTES, states: “This collaboration between two successful biotech companies co-marketing products needed in the life sciences has today established a new offering for researchers worldwide. We look forward to seeing this grow in the future.” Michael Piontek, Managing Director of ARTES Biotechnology, added: “The combination of development and manufacturing capabilities at both ARTES and our partner Basic Pharma enables the launch of human albumin today and several new peptides and proteins in the near future.”
Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his satisfaction with the progress; "This collaboration has been instrumental in realizing our vision of offering reagents for research applications. Our joint efforts with ARTES have paved the way for the release of Human Serum Albumin, marking a significant milestone in our strategic collaboration." Bob Kool, Managing Director at Basic Pharma, further emphasized: “The synergy between ARTES and Basic Pharma has been remarkable. We are excited about the potential impact of rHSA and are looking forward in this collaboration towards the development of pharmaceutical grade biologicals.”
